Open AccessQuality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer
Author(s) -
Vijay Patil,
Vanita Noronha,
Amit Joshi,
Anuradha Chougule,
Atanu Bhattacharjee,
Alok Goel,
Vikas Talreja,
Nandini Me,
Anant Ramaswamy,
Ashay Karpe,
Nikhil Pande,
Arun Chandrasekharan,
Abhishek Mahajan,
Amit Janu,
Nilendu Purandare,
Kumar Prabhash
Publication year - 2019
Publication title -
cancer research, statistics, and treatment/cancer research, statistics and treatment
Language(s) - English
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_17_19
Subject(s) - pemetrexed , gefitinib , carboplatin , medicine , epidermal growth factor receptor , oncology , randomization , randomized controlled trial , chemotherapy , cancer , cisplatin